Benign Prostatic Hyperplasia Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027

Published on : Dec-2019 | List of Tables : 38 | List of Figures : 106 | No. of Pages : 170 | Report Code : FACT4412MR | Format :

Educational Campaigns Augmenting Patient Base for Benign Prostatic Hyperplasia Treatment

There has been alarming rise in the number of patients suffering from benign prostatic hyperplasia (BPH), demanding central authorities to take strong action and control the progression

progression of this condition. According to a study published by the Canadian Journal of Urology, around 50% men are likely to suffer from BPH by the age of 50 years. This has led to an increase in awareness campaigns by central healthcare bodies. For instance, every year, September is observed as the 'National Prostate Health Month' in North America, aimed at educating men regarding the risks pertaining to BPH conditions, which is increasing the patient base for availing diagnosis and proper treatment. On the back of the steady rise in demand for therapeutics, a recent study by Fact.MR portends that, the benign prostatic hyperplasia treatment market would record a value tantamount to US$ 12 Bn by 2027.

growth potential of benign prostatic hyperplasia treatment market by treatment

For detailed insights on market taxonomy, request a sample copy of the report here.

Loss of Patent Exclusivity Creating Lucrative Ground for Generic Drugs

Instances of patent expirations have been long-influencing the revenue of the benign prostatic hyperplasia treatment market. As per the study, 2024 will witness patent expiration of key BPH treatment drugs, such as Avodart, Cialis, Jalyn, and Rapaflo. Absence of branded drugs opens lucrative avenues for regional and local players to increase investments towards the development of generic drugs and biosimilar products. Low-cost impact of generic drugs limits the sales opportunities for branded drugs, which creates concerns for leading players, as they invest huge capital to fuel their R&D activities. Though the sales of generic drugs fillip the growth of the BPH treatment market, their revenue contribution is significantly lesser as compared to branded drugs.

Market Share of Minimally-invasive Surgeries to Grow, while Drug Class Retains Pole Position

Nearly 50% of the total revenue in the benign prostatic hyperplasia treatment market is projected to arrive from drug classes by 2027. Availability of short-term and long-term alpha inhibitors that lower blood pressure and improve blood flow is found to relieve symptoms of BPH, which has led and continues to lead to the high adoption of these drugs. However, introduction of surgeries and therapeutics that relieve symptoms in one go in tandem with rising awareness regarding the side-effects of drugs, such as dizziness and nausea, is likely to move the market share accounted by minimally-invasive surgeries to a higher value.

opportunity assessment in benign prostatic hyperplasia treatment market by end user

For detailed regional analysis, request a sample copy of the report here.

Rise in Medical Tourism Catapulting Indian Benign Prostatic Hyperplasia Treatment Market

According to the Fact.MR study, the typical cost of transurethral resection of the prostate (TURP) in the U.S. ranges from US$ 8,000 to US$ 12,000, while cost of the same surgery in India is significantly lower (around US$ 1,500 to US$ 6,000). Cost benefits of TURP surgery in India are despite the use of cutting-edge technology and diagnostic equipment by surgeons for offering better patient outcomes. This is creating a novel revenue stream for the benign prostatic hyperplasia treatment market through medical tourism, especially driven from patients from Western countries such as the U.S. and the U.K. Also, hospitals—both, private and public—are free from long waitlists, and India has also relaxed visa policies, which further turns the country favourable for medical tourism.

A similar trend is being witnessed in the BPH treatment market in Japan. High technological advancements are complementing developmental efforts of manufacturers, such as Olympus Corporation, Astellas Pharma, Inc., Asahi Kasei Corporation, operating in Japan. On the back of medical tourism strengthening demand and intense R&D efforts ensuring long-term supply, the benign prostatic hyperplasia treatment market in Asia Pacific is witnessing an accelerated pace, projected to expand at a CAGR of 7.3% during the forecast period.

Benign Prostatic Hyperplasia (BPH) Treatment Market – Scope of the Study

The study on the benign prostatic hyperplasia (BPH) treatment market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that have been influencing the growth of the market. This exclusive study provides incisive insights regarding recent developments in the benign prostatic hyperplasia treatment market, by analysing the historical data for the period of 2017-2019, while the duration 2020-2027 is considered as the forecast period.

Evaluation of the benign prostatic hyperplasia treatment market’s revenue has been calculated in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the benign prostatic hyperplasia treatment market. Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing growth of the BPH treatment market during the forecast period. This detailed study provides information into the key dynamics, and their influence on the benign prostatic hyperplasia treatment market during the forecast period.

The report also provides information into the key challenges and threats that could deter the growth potential of players in the benign prostatic hyperplasia treatment market. The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global BPH treatment market. With a view of aiding stakeholders in the benign prostatic hyperplasia treatment market, the study comprises a detailed section on the competition analysis.

This exclusive study offers a dashboard view of the benign prostatic hyperplasia treatment market, with detailed information about the market players, based on overall revenue, key developments, and their market presence. Additionally, key strategies of players in the benign prostatic hyperplasia treatment market have also been included in this comprehensive study.

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type

End User

Region

Drug Classes

  • Alpha Blockers
  • 5-Alpha-reductase Inhibitors (5-ARIs)
  • Phosphodiesterase-5 Enzyme Inhibitors
  • Others

Hospitals

North America

Minimally-invasive Surgeries

  • Transurethral Resection of the Prostate (TURP)
  • Transurethral Incision of the Prostate (TUIP)
  • Robotic Surgeries
  • Transurethral Microwave Thermotherapy (TUMT)
  • Prostatic Urethral Lift
  • Others

Ambulatory Surgical Centres

Europe

Laser Therapy

Specialty Clinics

Asia Pacific

Others

Others

Latin America

 

 

Middle East & Africa

Revenue of the benign prostatic hyperplasia treatment market has been estimated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate (CAGR %) has been estimated for all segments during the forecast period 2020-2027, considering 2019 as the base year, in the benign prostatic hyperplasia treatment market.

Research analysts of the study on the benign prostatic hyperplasia treatment market have focused on leading, prominent, and emerging players, which include Olympus Corporation, Boston Scientific Corporation, LISA Laser, Teleflex Incorporated, Urologix, LLC, and Endo International PLC.

Benign Prostatic Hyperplasia Market – Research Methodology

The primary objective of this exclusive study on the BPH treatment market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2027. The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the benign prostatic hyperplasia treatment market, and recalibrate the adoption rate of benign prostatic hyperplasia treatment in key regions across the world.

1. Preface 

     1.1. Report Scope and Market Segmentation 

     1.2. Research Highlights

2. Assumptions and Research Methodology 

     2.1. Assumptions and Acronyms Used

     2.2. Research Methodology

3. Executive Summary

     3.1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

     3.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Market Snapshot

4. Market Overview

     4.1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Treatment Overview 

     4.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market: Key Industry Developments

     4.3. Market Dynamics

     4.4. Drivers and Restraints Snapshot Analysis

     4.5. Drivers

         4.5.1. Increasing Aging Men Population All Over the World

         4.5.2. Expanding Patient Pool Due to Other Risk Factors

     4.6. Restraints

         4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition

         4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs

     4.7. Opportunities

     4.8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Revenue Projections (US$ Mn), 2020–2027

5. Key Insights

     5.1. Clinical Trial Pipeline Analysis

     5.2. U.S. Prevalence of Benign Prostatic Hyperplasia

     5.3. Re-imbursement Scenario

     5.4. Key Merger and Acquisitions

     5.5. Number of Surgeries (Unit Procedures) Performed (2019)

     5.6. Competitive Market Share Analysis By Company (2019)

     5.7. Average Cost of Benign Prostatic Hyperplasia (BPH) Treatment 

     5.8. Product/Brand Analysis - 2018

         5.8.1. Urolift

         5.8.2. Rezum

6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by Treatment

     6.1. Introduction

     6.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         6.2.1. Drug Class

             6.2.1.1. Alpha-Blockers

             6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             6.2.1.4. Others

         6.2.2. Minimally Invasive Surgeries

             6.2.2.1. Transurethral resection of the prostate (TURP)

             6.2.2.2. Transurethral incision of the prostate (TUIP)

             6.2.2.3. Robotic Surgeries

             6.2.2.4. Transurethral microwave thermotherapy (TUMT) 

             6.2.2.5. Prostatic Urethral lift 

             6.2.2.6. Others

         6.2.3. Laser Therapy

         6.2.4. Others

     6.3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by Treatment

     6.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by End-user

     7.1. Introduction

     7.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         7.2.1. Hospitals

         7.2.2. Ambulatory Surgical Centers

         7.2.3. Specialty Clinics

         7.2.4. Others

     7.3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by End-user

     7.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by Region

     8.1. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Region, 2020–2027 

         8.1.1. North America

         8.1.2. Europe

         8.1.3. Asia Pacific

         8.1.4. Latin America

         8.1.5. Middle East & Africa

     8.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, by Region

     8.3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis

     9.1. North America Benign Prostatic Hyperplasia (BPH) Treatment Market 

     9.2. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

     9.3. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         9.3.1. Drug Class

             9.3.1.1. Alpha-Blockers

             9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             9.3.1.4. Others

         9.3.2. Minimally Invasive Surgeries

             9.3.2.1. Transurethral resection of the prostate (TURP)

             9.3.2.2. Transurethral incision of the prostate (TUIP)

             9.3.2.3. Robotic Surgeries

             9.3.2.4. Transurethral microwave thermotherapy (TUMT) 

             9.3.2.5. Prostatic Urethral lift 

             9.3.2.6. Others

         9.3.3. Laser Therapy

         9.3.4. Others

         9.3.5. 

     9.4. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         9.4.1. Hospitals

         9.4.2. Ambulatory Surgical Centers

         9.4.3. Specialty Clinics

         9.4.4. Others

     9.5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast, by Country

         9.5.1. U.S.

         9.5.2. Canada

     9.6. North America Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis 

         9.6.1. By Treatment

         9.6.2. By End-user

         9.6.3. By Country

10. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis

     10.1. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market 

     10.2. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

     10.3. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         10.3.1. Drug Class

             10.3.1.1. Alpha-Blockers

             10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             10.3.1.4. Others

         10.3.2. Minimally Invasive Surgeries

             10.3.2.1. Transurethral resection of the prostate (TURP)

             10.3.2.2. Transurethral incision of the prostate (TUIP)

             10.3.2.3. Robotic Surgeries

             10.3.2.4. Transurethral microwave thermotherapy (TUMT) 

             10.3.2.5. Prostatic Urethral lift 

             10.3.2.6. Others

         10.3.3. Laser Therapy

         10.3.4. Others

     10.4. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         10.4.1. Hospitals

         10.4.2. Ambulatory Surgical Centers

         10.4.3. Specialty Clinics

         10.4.4. Others

     10.5. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast, by Country/Sub-region

         10.5.1. U.K.

         10.5.2. France

         10.5.3. Germany

         10.5.4. Spain

         10.5.5. Italy

         10.5.6. Rest of Europe

     10.6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis 

         10.6.1. By Treatment

         10.6.2. By End-user

         10.6.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis

     11.1. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Key Findings

     11.2. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

     11.3. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         11.3.1. Drug Class

             11.3.1.1. Alpha-Blockers

             11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             11.3.1.4. Others

         11.3.2. Minimally Invasive Surgeries

             11.3.2.1. Transurethral resection of the prostate (TURP)

             11.3.2.2. Transurethral incision of the prostate (TUIP)

             11.3.2.3. Robotic Surgeries

             11.3.2.4. Transurethral microwave thermotherapy (TUMT) 

             11.3.2.5. Prostatic Urethral lift 

             11.3.2.6. Others

         11.3.3. Laser Therapy

         11.3.4. Others

     11.4. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         11.4.1. Hospitals

         11.4.2. Ambulatory Surgical Centers

         11.4.3. Specialty Clinics

         11.4.4. Others

     11.5. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast, by Country/Sub-region

         11.5.1. China

         11.5.2. India

         11.5.3. Japan

         11.5.4. Australia & New Zealand

         11.5.5. Rest of Asia Pacific

     11.6. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis 

         11.6.1. By Treatment

         11.6.2. By End-user

         11.6.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis

     12.1. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Key Findings

     12.2. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

     12.3. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         12.3.1. Drug Class

             12.3.1.1. Alpha-Blockers

             12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             12.3.1.4. Others

         12.3.2. Minimally Invasive Surgeries

             12.3.2.1. Transurethral resection of the prostate (TURP)

             12.3.2.2. Transurethral incision of the prostate (TUIP)

             12.3.2.3. Robotic Surgeries

             12.3.2.4. Transurethral microwave thermotherapy (TUMT) 

             12.3.2.5. Prostatic Urethral lift 

             12.3.2.6. Others

         12.3.3. Laser Therapy

         12.3.4. Others

     12.4. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         12.4.1. Hospitals

         12.4.2. Ambulatory Surgical Centers

         12.4.3. Specialty Clinics

         12.4.4. Others

     12.5. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast, by Country/Sub-region

         12.5.1. Brazil

         12.5.2. Mexico

         12.5.3. Rest of Latin America

     12.6. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis 

         12.6.1. By Treatment

         12.6.2. By End-user

         12.6.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis

     13.1. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market 

     13.2. Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

     13.3. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by Treatment

         13.3.1. Drug Class

             13.3.1.1. Alpha-Blockers

             13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

             13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

             13.3.1.4. Others

         13.3.2. Minimally Invasive Surgeries

             13.3.2.1. Transurethral resection of the prostate (TURP)

             13.3.2.2. Transurethral incision of the prostate (TUIP)

             13.3.2.3. Robotic Surgeries

             13.3.2.4. Transurethral microwave thermotherapy (TUMT) 

             13.3.2.5. Prostatic Urethral lift 

             13.3.2.6. Others

         13.3.3. Laser Therapy

         13.3.4. Others

     13.4. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast, by End-user

         13.4.1. Hospitals

         13.4.2. Ambulatory Surgical Centers

         13.4.3. Specialty Clinics

         13.4.4. Others

     13.5. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast, by Country/Sub-region

         13.5.1. GCC Countries

         13.5.2. South Africa

         13.5.3. Rest of Middle East & Africa

     13.6. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Attractiveness Analysis 

         13.6.1. By Treatment

         13.6.2. By End-user

         13.6.3. By Country/Sub-region

14. Competition Landscape (Pharmaceutical Companies)

     14.1. Company Profiles

         14.1.1. Abbott

             14.1.1.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.1.2. Financials

             14.1.1.3. Recent Developments

             14.1.1.4. Strategy

         14.1.2. Allergan Plc

             14.1.2.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.2.2. Financials

             14.1.2.3. Recent Developments

             14.1.2.4. Strategy

         14.1.3. Astellas Pharma, Inc.

             14.1.3.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.3.2. Financials

             14.1.3.3. Recent Developments

             14.1.3.4. Strategy

         14.1.4. Asahi Kasei Corporation

             14.1.4.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.4.2. Financials

             14.1.4.3. Recent Developments

             14.1.4.4. Strategy

         14.1.5. Boehringer Ingelheim GmbH 

             14.1.5.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.5.2. Financials

             14.1.5.3. Recent Developments

             14.1.5.4. Strategy

         14.1.6. GlaxoSmithKline Plc.

             14.1.6.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.6.2. Financials

             14.1.6.3. Recent Developments

             14.1.6.4. Strategy

         14.1.7. Pfizer, Inc.

             14.1.7.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.7.2. Financials

             14.1.7.3. Recent Developments

             14.1.7.4. Strategy

         14.1.8.  Sanofi SA

             14.1.8.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.8.2. Financials

             14.1.8.3. Recent Developments

             14.1.8.4. Strategy

         14.1.9. Teva Pharmaceutical Industries Ltd.

             14.1.9.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.9.2. Financials

             14.1.9.3. Recent Developments

             14.1.9.4. Strategy

         14.1.10. Merck & Co., Inc.

             14.1.10.1. Overview (HQ, Employee Strength, Business Segments)

             14.1.10.2. Financials

             14.1.10.3. Recent Developments

             14.1.10.4. Strategy

15. Competition Landscape (Medical Devices/Service Provider Organizations)

     15.1. Company Profiles

         15.1.1. Boston Scientific Corporation

             15.1.1.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.1.2. Financials

             15.1.1.3. Recent Developments

             15.1.1.4. Strategy

         15.1.2. Teleflex Incorporated

             15.1.2.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.2.2. Financials

             15.1.2.3. Recent Developments

             15.1.2.4. Strategy

         15.1.3. Endo International Plc.

             15.1.3.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.3.2. Financials

             15.1.3.3. Recent Developments

             15.1.3.4. Strategy

         15.1.4. Urologix, LLC

             15.1.4.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.4.2. Financials

             15.1.4.3. Recent Developments

             15.1.4.4. Strategy

         15.1.5. LISA Laser

             15.1.5.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.5.2. Financials

             15.1.5.3. Recent Developments

             15.1.5.4. Strategy

         15.1.6. Olympus

             15.1.6.1. Overview (HQ, Employee Strength, Business Segments)

             15.1.6.2. Financials

             15.1.6.3. Recent Developments

             15.1.6.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benign Prostatic Hyperplasia Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027